X

Trial Profile

A Randomized, Adaptive Design, Proof of Concept, Single Dose Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPN-019 (Primary)
Indications COVID 2019 infections
Focus Proof of concept; Therapeutic Use
Sponsors OptiNose

Most Recent Events

26 Apr 2022 Status changed from recruiting to discontinued as per sponsor decision.
11 Aug 2021 Status changed from planning to recruiting, according to an optinose inc media release.
05 May 2021 According to an optinose inc media release, egulatory approval to initiate the pilot study is pending. The Company expects top-line results from this study in second quarter 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com